HDAC9 and Parkinson disease: Along with the neuroprotective phenotype observed towards degenerating dopaminergic neurons, our findings on the use of a SIRT 2 inhibitor in microglia highlights the advantage of more selective HDAC inhibition, more specifically SIRT 2 inhibition, for therapeutic potential in PD.